Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.

Zhang L, Du H, Xiao TW, Liu JZ, Liu GZ, Wang JX, Li GY, Wang LX.

Biomed Pharmacother. 2015 Oct;75:83-7. doi: 10.1016/j.biopha.2015.08.037. Epub 2015 Sep 15.

PMID:
26463635
2.

[Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].

Yao WK, Wang YP, Peng F, Zheng Y, Zou YB, Gao JN, Liu XL.

Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):818-22. doi: 10.3760/cma.j.issn.0529-5807.2012.12.006. Chinese.

PMID:
23324230
3.

Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.

Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, Watanabe R, Takasaki H, Motomura S, Kobayashi S, Yokose T, Ishigatsubo Y, Sakai R.

Leuk Lymphoma. 2014 Dec;55(12):2721-7. doi: 10.3109/10428194.2014.893311. Epub 2014 Mar 19.

PMID:
24528218
4.

Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.

Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM.

Ann Hematol. 2015 Nov;94(11):1865-73. doi: 10.1007/s00277-015-2490-0. Epub 2015 Sep 2.

PMID:
26327569
5.

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.

Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, Seymour JF, Hicks RJ, Gill D, Crooks P, Gould C, Jones K, Griffiths LR, Talaulikar D, Jain S, Tobin J, Gandhi MK.

Lancet Haematol. 2015 Oct;2(10):e445-55. doi: 10.1016/S2352-3026(15)00150-7. Epub 2015 Oct 1.

PMID:
26686046
6.

CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.

Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M.

Am J Hematol. 2013 Apr;88(4):273-6. doi: 10.1002/ajh.23398. Epub 2013 Mar 5.

7.

LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.

Peng W, Wu J, Feng J.

Clin Exp Med. 2017 Feb;17(1):1-8. doi: 10.1007/s10238-015-0396-8. Epub 2015 Oct 16.

PMID:
26475621
8.

Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.

Yoon JH, Kim JW, Jeon YW, Lee SE, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Min WS, Park CW, Cho SG.

Korean J Intern Med. 2015 May;30(3):362-71. doi: 10.3904/kjim.2015.30.3.362. Epub 2015 Apr 29.

9.

Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Lee HJ, Shin DH, Kim KB, Shin N, Park WY, Lee JH, Choi KU, Kim JY, Lee CH, Sol MY.

Leuk Lymphoma. 2014 Sep;55(9):2056-63. doi: 10.3109/10428194.2013.858816. Epub 2014 Feb 24.

PMID:
24304372
10.

Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.

Gong QX, Lu TX, Liu C, Wang Z, Liang JH, Xu W, Li JY, Zhang ZH, Chen Q.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15825-35. eCollection 2015.

11.

Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.

Wang C, Li W, Liu C, He H, Bai O.

Blood Cells Mol Dis. 2016 Mar;57:42-9. doi: 10.1016/j.bcmd.2015.12.004. Epub 2015 Dec 8.

PMID:
26852654
12.

[Expression and clinical significance of CD40 in diffuse large B-cell lymphoma].

Wang S, Wang YP, Hao YY, Zheng Y.

Zhonghua Bing Li Xue Za Zhi. 2013 Dec;42(12):819-23. Chinese.

PMID:
24507100
13.

Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL).

Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, Zivković R, Hajder J, Stanisavljevic N, Mihaljevic B.

Med Oncol. 2012 Dec;29(5):3515-21. doi: 10.1007/s12032-012-0232-x. Epub 2012 Apr 13.

14.

[Expression and clinical significance of Ki-67 in diffuse large B cell lymphoma].

Zhou Y, Zhao Y, Bo J, Li YF, Ma C, Shi YN.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1162-6. doi: 10.7534/j.issn.1009-2137.2013.05.015. Chinese.

PMID:
24156426
16.
17.

SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.

Tomita N, Sakai R, Fujisawa S, Fujimaki K, Taguchi J, Hashimoto C, Ogawa K, Yamazaki E, Ishigatsubo Y.

Cancer Sci. 2012 Aug;103(8):1518-23. doi: 10.1111/j.1349-7006.2012.02331.x. Epub 2012 Jul 4.

18.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.

19.

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y.

Medicine (Baltimore). 2017 Apr;96(15):e6398. doi: 10.1097/MD.0000000000006398.

20.

The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, Vose J, Lenz G, Staudt L, Chan W, Weisenburger DD.

Am J Clin Pathol. 2011 Jan;135(1):54-61. doi: 10.1309/AJCPJX4BJV9NLQHY.

PMID:
21173124

Supplemental Content

Support Center